Directorate change

BioPharma Credit PLC

15 September 2026

 

15 September 2026

BIOPHARMA CREDIT PLC

(The "Company")

Appointment of New Director

The Board of Directors of the Company is pleased to announce the appointment of Graeme Proudfoot as a non-executive Director with effect from 15 September 2026.

Mr Proudfoot has considerable asset management experience and expertise, having spent the majority of his executive career at Invesco, latterly as Managing Director, EMEA and Chief Executive Officer of Invesco Pensions. Prior to joining Invesco, Graeme began his career at Wilde Sapte Solicitors, practising as a corporate finance lawyer in London and New York. He previously served as a director of VPC Specialty Lending Investments plc.

Mr Proudfoot is Chairman and non-executive Director of BlackRock Income & Growth Investment Trust and a non-executive Director of The Schiehallion Fund.

The Company makes this announcement in accordance with UKLR 6.4.6. There are no other matters to be disclosed under UKLR 6.4.8.  

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

[phone]

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

[phone]

[e-mail]

LEI: 213800AV55PYXAS7SY24

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist debt investor from life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

END